Wastewater testing during the South African 2022-2023 measles outbreak demonstrates the potential of environmental surveillance to support measles elimination

Nkosenhle Ndlovu[¶1], Kerrigan M. McCarthy [¶*1,3,4], Victor Vusi Mabasa[1], Chenoa Sankar[1], Nosihle Msomi[1], Emmanuel Phalane[1], Natasha Singh[1], Sipho Gwala[1], Fiona Els[1,2,4], Mokgaetji Macheke[1], Sibonginkosi Maposa[1], Mukhlid Yousif[1,3]

[1]Wastewater Genomics, Centre for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, Gauteng, South Africa,

[2]Gauteng City-Region Observatory (GCRO), a Partnership of the University of Johannesburg, the University of the Witwatersrand, the Gauteng Provincial Government and Organised Local Government in Gauteng (SALGA), Gauteng, South Africa.

[3]Department of Virology, School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng, South Africa.

[4] School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng, South Africa.

[¶]Joint first authors

*Corresponding author

Address: Centre for Vaccines and Immunology, National Institute for Communicable Diseases, 1 Modderfontein Rd, Sandringham, Johannesburg, 2192, South Africa.

E-mail: kerriganm@nicd.ac.za

Author contributions

Name (Abbreviation)	Contributions	ORCID ID
Nkosenhle Ndlovu (NN)	Data curation, Formal analysis, Investigation, Writing – original draft	0000-0002-0294-0720

Kerrigan McCarthy (KM)	Conceptualisation, Funding acquisition, Formal analysis, Methodology, Supervision, Validation, Writing original draft, Writing – review and editing	0000-0001-8958-9795
Victor Vusi Mabasa (VVM)	Conceptualisation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Validation, Writing – review and editing	0000-0002-0564-0344
Chenoa Sankar (CS)	Data curation, Formal analysis, Investigation, Methodology, Software, Writing – review and editing	0009-0007-7869-2026
Nosihle Msomi (NM)	Data curation, Formal analysis, Investigation, Software, Writing – review and editing	0000-0003-0053-0928
Emmanuel Phalane (EP)	Data curation, Investigation, Writing – review and editing	0000-0003-1208-3037
Natasha Singh (NS)	Investigation, Writing – review and editing	0000-0003-3074-8303
Sipho Gwala (SG)	Investigation, Writing – review and editing	0000-0002-8912-5584
Fiona Els (FE)	Writing – review and editing	0000-0002-4169-813X
Mokgaetji Macheke (MM)	Investigation, Writing – review and editing	0000-0002-5179-8230
Sibonginkosi Maposa (SM)	Investigation, Project administration, Resources, Supervision, Writing – review and editing	0000-0003-0575-1420
Mukhlid Yousif (MY)	Conceptualisation, Funding acquisition, Methodology, Supervision Validation, Writing – review and editing	0000-0002-8707-2255

Abstract

Background

Surveillance is a key component of the WHO 2030 measles elimination strategy. Wastewater and environmental surveillance (WES) has successfully supported polio surveillance, however, it has not been applied to measles control.

Aim

We developed a measles virus (MeV) digital-PCR (dPCR) assay using WHO recommended clinical primer-probes and applied it to retained wastewater samples from national SARS-CoV-2 wastewater sentinel surveillance sites. We compared results with national clinical measles surveillance data.

Setting

Wastewater concentrates were collected from 47 SARS-CoV-2 wastewater surveillance sites across South Africa.

Methods

We determined the limit of detection using the assay on serial dilutions of MeV positive controls. Subsequently we conducted batch testing on wastewater concentrates retained at -20°C for up to 15 months and compared wastewater results with national laboratory-confirmed measles case data by district and epidemiological week.

Results

Our assay identified 43/2149 (2%) samples containing MeV RNA in concentrations ranging from 1.97 – 165.8 genome copies/mL. Amongst 27 week-district instances where at least one MeV positive wastewater sample was detected, no clinical cases were detected in 13 (48%) of these.

Conclusion

Despite likely RNA degradation, it was possible to detect MeV in wastewater samples in districts where clinical surveillance failed to identify cases.

Contribution

WES has evident potential to strengthen surveillance in support of the measles elimination agenda. With immediate processing and improved wastewater RNA concentration methods, WES sensitivity will likely increase.

Funding

This work was funded by BMGF (INV-049271)

Introduction

Measles, a highly infectious, vaccine-preventable viral infection, is targeted by the World Health Organization (WHO) for elimination by 2030[1]. Measles incidence and mortality have declined dramatically since the year 2000 due to the increase in global vaccination coverage from 72% in 2000 to 83% in 2022, despite a transient decline in 2021 due to the COVID-19 pandemic. Global measles indicators have improved with measles deaths falling between 2000 and 2022 from 1,072,800 to 136,200 deaths and measles incidence dropping from 145 cases per million, to 29 cases per million [2]. Despite these improvements, measles is still a leading cause of death in children under the age of 5 years in low- and middle-income countries[2]. In support of the 2021-2030 strategic framework for measles and rubella elimination, ongoing global efforts are in place to control viral transmission[1]. Efforts are targeted at ensuring high vaccination coverage and implementation of sensitive surveillance systems[1]. Interventions include the provision of two doses of measles vaccine before the age of 5 years as part of the expanded programme of immunisation (EPI), supplementary immunisation activities (SIAs) every 4-5 years where routine vaccination coverage does not achieve 95% coverage, fever-rash surveillance, and rapid, outbreak response[1]. In South Africa, intermittent measles outbreaks have continued to occur over the last 25 years, the largest of which led to over 21,000 laboratory-confirmed cases 2009-2011[3]. Most recently, an outbreak of over 1,383 cases commenced in 2022 following apparent importation of the B3 genotype from neighbouring countries.

As measles elimination targets and dates approach, the WHO and national public health authorities rely increasingly on measles surveillance to support program monitoring[1]. Theoretically, measles surveillance should be highly sensitive, as asymptomatic infection does not occur, and a robust, though non-specific case definition is easily applied[4]. However, four factors may limit the sensitivity and/or utility of clinical measles surveillance. Firstly, health system factors including clinician awareness, propensity to test and notify, financial allocations for testing, and submission of diagnostic specimens often limit submission of diagnostic specimens[5]. Secondly, in our experience, patients and their caregivers may not seek medical care if their clinical presentation is uncomplicated as may occur in the context of older children, and recognized outbreaks. Thirdly, incomplete provision of clinical data (such as date of rash onset and vaccination history) leads to challenges in case classification, contact tracing and outbreak response[6]. Fourthly, urine or throat swabs are less frequently submitted for polymerase chain reaction (PCR) testing, rendering PCR detection and genomic sequencing, and thus case classification especially difficult during outbreak contexts[7].

Wastewater and environmental surveillance (WES) has been a component of the Global Polio Elimination Initiative since 2003. In recent years, WES has been applied across the globe to provide complementary surveillance data during the SARS-CoV-2 pandemic, the multicountry mpox clade II outbreak[8], and other pathogens. Regarding measles surveillance, the earliest application of WES

was conducted by Benschkop *et al* who detected MeV in 6/56 (10.7%) wastewater samples collected for polio surveillance during a measles outbreak in a vaccine-hesitant community 2013[9]. A number of laboratory protocols for measles detection have been developed[10–14] and applied to outbreak contexts retrospectively[15] and prospectively[12,16]. However, to date measles WES is yet to be implemented systematically as part of routine programmatic surveillance.

In this paper, we describe the development, optimisation and validation of a reverse transcriptase digital PCR (RT-dPCR) assay for detection and quantification of MeV in wastewater, which we applied retrospectively to wastewater samples from a national sentinel surveillance network. As wastewater samples were collected during the ongoing national measles outbreak that began in October 2022, we compared wastewater findings with clinical surveillance data to explore the role of WES as a complementary surveillance tool for programmatic purposes.

Methods

Study design and setting

In 2020, the National Institute of Communicable Diseases (NICD) expanded polio testing at 18 WES sentinel sites to include SARS-CoV-2 across nine provinces of South Africa[17]. Over time, and dependent on funding, the number and location of sites changed. Presently, the NICD coordinates a national WES sentinel surveillance network comprising sampling sites at 28 wastewater treatment plants (WWTPs) across nine South African provinces and border transit points, and a network of 19 community sampling sites located within the catchment areas of three large WWTPs in the densely populated Gauteng Province (Figure 1).

116 **Figure 1. Sampling locations at South African wastewater treatment plants (national sentinel**

117 **surveillance sites) and in-line sewer sampling sites (sub-catchment areas in City of Tshwane,**

118 **Johannesburg and Ekurhuleni, inset). Figure created using QGIS (version 3.42.3) with**

119 **opensource shapefiles from https://www.demarcation.org.za/**

121 Laboratory methods

Wastewater sample collection, concentration and storage.

Grab samples of one litre were collected monthly, weekly or biweekly from collection sites by

immersion of a Virocide® treated bucket lowered into the middle of the sewage stream, at

approximately the same time of day. Samples were decanted into one litre plastic screwtop bottles and

transported on ice to the NICD within 24 hours of collection. On receipt, samples were refrigerated at

4°C, and within 24-48 hours, 200mL of raw sewage was centrifuged at 4650 x g at 4°C for 30 minutes

to clarify the sample. Then 70mL of supernatant was centrifuged at 3500 x g for 15 minutes through a

Centricon® Plus-70 centrifugal ultra-filter (Merck Millipore, Tullagreen, Ireland). Material retained in

the filter was eluted to a concentrate volume of approximately 1 mL. Concentrates were processed

immediately for SARS-CoV-2, and the balance was retained at -20 °C for extraction and PCR once
MeV and other assays were developed and validated.

Primers and probes for measles and pepper mild mottle virus (PMMoV) detection

Primers and probes specific for MeV and pepper mild mottle virus (PMMoV) were identified from
previously described methods[18,19] (Table 1). We targeted a fragment of the N gene and designed
'MeV-WT' and genotype A-specific primers and a probe to differentiate wild-type MeV genotypes
dominant in recent South African outbreaks (B3, D8 and H1) from vaccine strain (genotype A) (Table
1, Figure 2).

Using the measles RNA-positive control provided by the Global Measles Reference Laboratory
Network (GMRLN), the commercially available OMZYTA® MMR live attenuated vaccine (MSD
(Pty) Ltd), derived from Enders' attenuated Edmonston strain, and RNA from clinical samples
collected during an outbreak in South Africa in 2022 as positive controls, we performed dPCR assays
in replicates of five using the method described below using the MeV pan, MeV-WT and genotype A-
specific primer-probe combinations to determine relative specificity.

Table 1. Primers, probes and source references used for PCR detection of measles virus (MeV)
and pepper mild mottle virus (PMMoV) in wastewater samples.

Virus	Target	Primer / probe name	Sequence (5'-3')	Ref
MeV pan	N gene	MVN1139	TGG CAT CTG AAC TCG GTA TCA C	[18]
		MVN1213R	TGT CCT CAG TAG TAT GCA TTG CAA	
		MVNP1163Probe-2	/56-TAMN/CCG AGG ATG CAA GGC TTG TTT CAG A/3BHQ_1/	
MeV vaccine (genotype A)	Nucleocapsid	VMA168F	GAGATTGGGGGGGCAAGGAAGAT	*
		VMA242R	GCATCACTTGCTCTGCTGGGCC	
		VMA190P	FAM-AGGAGGGTCAAACAGAGTCGA-MGB	
MeV wild-type (genotype non-A)	Nucleocapsid	VMB168F	RRGATTRGGGGGYAAGGARGAY	*
		VMB242R	RCATCACTTGMTCTGCTRGRYY	
		VMB190P	ROX-AGGAGGGTCARACAGARYCGR	
PMMoV	Unspecified 5' end	PMMOV_END_F	TTC GCA CTG CAC GGA TAA AGT AT	[19]
		PMMOV_END_R	GCC CCA AAT TCA TCT GCT GGA A	

| | | PMMOV_END_M | /56-FAM/ACG CTG TCG /ZEN/CTT TGC/3IABKFQ/ | |

149   *in house

150
151   **Figure 2.** Primers and probe design to differentiate measles virus vaccine strain (Edmonston) from wild
152   genotypes (B3, D8, and H1) using the N gene.
153

Digital PCR optimisation and determination of limit of detection

We determined the limit of detection (LoD) (defined as the concentration in genome copies/uL of the
lowest dilution that is theoretically detectable when using optimized methods) with a single- and
duplex RT-dPCR assay using pan-MeV primers and probe with and without previously described
rubella virus (RuV) primers and probe[20]. In triplicate, we serially diluted the MeV RNA-positive
control provided by the GMRLN in 14 two-fold dilutions (neat to 1:16,384) and subjected these to the
QIAcuity OneStep Advanced Probe RT-dPCR assay (Qiagen, Hilden, Germany) on QIAcuity® One,
5plex System dPCR platform (Qiagen) using 96-well 8.5k nanoplates. The pan-MeV RT-dPCR
master mix contained 3 µL of 4× QIAcuity One-Step Advanced Probe Master Mix, 0.12 µL of 100×
One-Step Advanced RT-Mix, 0.6 µL of 20× primer-probe mix MeV (TAMRA), 0.6 µL of 20× RuV
primer-probe mix (Cy5) and 1 µL of QIAcuity Enhancer GC. The same master mix set-up was used
for vaccine-specific primers and probe reactions. Cycling conditions for RT-dPCR were reverse
transcription at 50°C for 40 minutes, RT enzyme inactivation at 95°C for 1 minute and 45 cycles of
annealing & extension at 60°C.

Each RNA dilution of the positive control was also tested using RT-qPCR conducted on the Applied
Biosystems® 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the
QIAcuity One-Step Advanced Probe Master Mix. The RT-qPCR master mix contained 4x One-Step
Advanced Probe Master Mix 6.25 µL, 100x One-Step Advanced RT-Mix 0.25 µL, 20x primer-probe
mix MV (TAMRA) 1.25 µL, 20x primer-probe mix RV (Cy5) 1.25 µL, Enhancer GC 2 µL, RNAse-
free water 6 µL.

We defined the assay LoD as one positive partition on the QIAcuity® One, 5plex System dPCR
platform (Qiagen), provided that ≥70% of the total partitions are valid. However, when expressed in
copies/µL or copies/mL, the LoD represents a range rather than a fixed value, as the calculation is

based on a Poisson distribution that incorporates both the number of valid partitions and the number

of positive partitions to estimate concentration. We did not determine the LoD in spiked wastewater,

however, we are satisfied that a single positive partition, in a raw wastewater sample even in the

absence of replicability, is a valid result. Our justification for this is as follows: 1) we observed single

positive partitions in serial dilutions of positive control when applying qPCR and dPCR to the same

dilutions; 2) replicability in the presence of extremely low concentrations of nucleic acid such as is

found in wastewater, is statistically highly unlikely; 3) in subsequent work (manuscript in progress),

we have successfully sequenced MeV from wastewater even when a single partition tested positive.

Testing of retained wastewater concentrates

Following thawing, over 2,100 retained concentrates from February 2021 (week 7) to March 2024

(week 10) were tested in batches of 92 samples for MeV and PMMoV. Total nucleic acids were

extracted from 200 µL of viral concentrate on the 96 KingFisher Flex Purification System (Thermo

Fisher Scientific, Waltham, MA USA) using the MagMAX™ Wastewater Ultra Nucleic Acid

Isolation kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, nucleic

acids were captured in 520 µL of lysis binding solution before they were washed in 1ml of Wash 1

and 3 solutions and eluted in 60 µL of elution buffer. We added 8µl of nucleic acids in the dPCR

reaction. We used the formula below to determine the genome copy number per milliliter of the raw

wastewater sample:

195
$$SC = (C_{rxn} * V_{rxn\ vol.} * (\frac{V_{elute}}{V_{NA}}) * (\frac{V_{total\ conc.}}{V_{conc.\ extracted}})) / V_{sample\ conc.}$$

SC = Sample concentration (gc/ml)
C_{rxn} = Concentration (gc/µl) obtained from dPCR machine.
$V_{rxn\ vol.}$ = Volume (µl) of the PCR reaction.
V_{elute} = Total volume (µl) of the extraction elute.
V_{NA} = Volume (µl) of nucleic acids used in the PCR reaction.
$V_{total\ conc.}$ = Total volume (µl) of the concentrate.
$V_{conc.\ extracted}$ = Volume (ml) of concentrate used for extraction.
$V_{sample\ conc.}$ = Volume of the wastewater sample concentrated.
204

Detection of wild-type and genotype A (vaccine strain) in MeV-positive wastewater samples

After identification of MeV positive wastewater samples, we returned to residual retained

concentrates from these samples and subjected them to a second extraction and PCR using the

QIAcuity® One, 5plex System (Qiagen, Hilden, Germany) as described above, using the in-house

vaccine- and wild-type specific primers to identify samples where wild-type and genotype A (vaccine)

was present (see Supplement). We used the commercially available OMZYTA® MMR live

attenuated vaccine (derived from Enders' attenuated Edmonston strain) and RNA from clinical

samples collected during an outbreak in South Africa, as positive controls for MeV pan and vaccine-
specific primer-probe combinations respectively.

Fever-rash surveillance and diagnostic testing

Fever-rash surveillance

The NICD in Johannesburg, South Africa is one of 86 accredited World Health Organization GMRLN
laboratories and conducts measles testing (IgM and IgG serology, PCR, and sequencing) for South
Africa and the southern Africa region[21]. Samples from suspected measles cases (any person with
fever, rash and one of cough, conjunctivitis or coryza) are collected by provincial and district health
department staff and transported on ice to the NICD. Serology testing is conducted using the
Euroimmun Anti-Measles Virus ELISA (IgM and IgG) (Lubeck, Germany). PCR testing is conducted
using the method described in Chapter 6 of the WHO Manual for the Laboratory-based Surveillance
of Measles, Rubella, and Congenital Rubella Syndrome[21,22] targeting a region of the N gene.
South African surveillance indicators have consistently achieved more than the required two non-
measles fever-rash cases/100,000[23].

When vaccination history is not provided (most specimens submitted for testing), NICD surveillance
protocols define a laboratory-confirmed case of measles as a positive IgM serologic test for MeV in a
person with fever, rash and one of cough, conjunctivitis or coryza. We extracted measles serology
results (including district where sample was collected and collection date, without identifying data)
for the period 16 February 2021 (week 7) to 08 March 2024 (week 10) from our NICD Centre for
Vaccines and Immunology database by district of South Africa on 29 March 2024.

Data analysis

Comparison of dPCR and qPCR results, determination of limit of detection and normalisation of data

236 We conducted univariable regression analysis using MS Excel comparing qPCR Ct thresholds and
237 dPCR genome copies/reaction for each dilution of the positive control in monoplex (MeV) and duplex
238 (MeV plus RuV) assays to determine the limit of detection (LoD) and to assist with interpretation of
239 low concentrations of MeV detected by dPCR. We normalised our data by determining the ratio of
240 MeV:PMMoV genome copies per microlitre.

Comparison of clinical surveillance and wastewater measles testing data at health district level by week

As public health responses to detection of measles cases are triggered by the number of cases detected
in a health district over one month[24], we elected to compare wastewater and clinical surveillance
data by health district. Further, we temporally limited each comparison to a single epidemiological
week, and, in a second analysis, to the epidemiological weeks before and after a week when a clinical
case was detected to accommodate for the period during which wild-type MeV is excreted[25]. We
conducted this analysis as follows: we grouped and tallied the total number of IgM-positive clinical
specimens submitted for testing by epidemiological week of sample collection and district of health
facility where the case was identified using case-line lists collected as part of national measles fever-
rash surveillance. We also grouped and tallied wastewater samples by epidemiological week and
district. We merged these clinical and wastewater results by epidemiological week and district and
eliminated week-district pairs where no wastewater samples were tested.

We defined a 'positive concordant wastewater-clinical pair' as any instance in a given
epidemiological-week in a specified district where at least one wastewater sample tested positive for
MeV and one clinical case was identified. Conversely, we defined a 'negative concordant pair' as one
where all wastewater and clinical samples tested negative or no clinical samples were submitted. The
remaining 'discordant' pairs were those where least one case was detected but all wastewater samples
were negative, or vice versa. We determined and described the proportion of concordant and
discordant week-district pairs and presented these in two-by-two tables. In concordant instances, we
also determined the relationship between the number of measles cases detected and the proportion
testing positive as well as the number of measles cases detected and the wastewater levels of MeV in
genome copies/mL using simple regression (MS Excel). When MeV was detected in wastewater, but
no clinical cases were detected in that district, we examined the clinical measles surveillance data in
neighboring districts. To do this, we summed, tabulated and visually inspected the measles cases from
neighboring districts in the same epidemiological week, and the weeks before and after.

Ethics

The protocol for this study was reviewed and approved by the University of the Witwatersrand
Human Research Ethics Committee (HREC) (MM220904). The National Department of Health's
Environmental Health and Expanded Programme of Immunisation directorates, which are responsible
for coordinating polio environmental surveillance, arranged permission from the municipal
departments of water and sanitation for the NICD to test wastewater from participating wastewater
treatment plants sites for polio, SARS-CoV-2 and other vaccine-preventable diseases. The City of
Tshwane, City of Ekurhuleni and City of Johannesburg gave permission to collect and test wastewater
samples from inspection holes located in their regions. Measles surveillance data is collected by the
NICD as part of the institution's responsibility to conduct national public health surveillance, in
accordance with the oversight provided by the University of the Witwatersrand's HREC (M210752)

Results

RT-dPCR assay optimisation and specificity

We optimized the QIAcuity OneStep Advanced Probe RT-dPCR assay by increasing the manufacturer's recommended cycling profile of 30s and cycle number of 40 to one minute and 45 cycles respectively to obtain optimal separation of positive and negative partitions on the RT-dPCR platform.

MeV pan primers detected every instance of spiked GMRLN positive control, spiked MMR live-attenuated vaccine and spiked MeV in known-MeV positive clinical samples collected during an outbreak in South Africa (Table 2). However, in-house genotype A-specific primers falsely detected vaccine strain when only wild-type strain was present in 2 of five instances (Table 2). Primer-probes designed to detect wild-type genotypes recently circulating in South Africa (B3, D8 and H1) were non-specific as they intermittently detected genotype A and lacked sensitivity (Table 2).

Table 2. Results of MeV (pan), genotype A and wild-type (genotype B3, D8 and H1)-specific primer-probe combinations when tested using appropriate controls*

Primer probe combination	Type of positive control (#positive /# tested)		
	Vaccine	CDC MeV positive control	Wild-type
MeV pan	5/5	5/5	5/5
MEV - genotype A	5/5	5/5	2/5[#]
MeV - WT	5/5*	5/5	2/5[1]

*Raw data in Table S1 of the supplement
*These results indicate that the WT PCR reactions are positive when only measles vaccine (genotype A) is present. Therefore MeV-WT PCR reactions are non-specific
[#]These results indicate the genotype A primers are positive in some instances when only WT is present. Therefore, the genotype A PCR reactions are non-specific
[1]These results indicate that wild-type primers were positive in only some instances when wild-type is present. Therefore MeV-WT lack sensitivity

Assay limit of detection

Following optimisation of qPCR and dPCR protocols for MeV pan and MeV pan multiplexed with RuV, we determined the relationship between the number of positive dPCR partitions and Ct values of qPCR (Figure 3). The limit of detection in duplex reaction with RuV was determined to be 0.346 - 0.494 gc/uL (1 positive partition in assays with 100% (8500/8500) valid partitions, or 1 positive partition in assays with 70% valid partitions (5950/8500) (Figure S1).

Figure 3. Validation of dPCR and qPCR assays (red = measles virus (MeV); blue=MeV duplexed with rubella virus (RuV)) using primer-probe combinations tested on serial dilutions (1:32 to 1:16,384) of WHO Global Measles and Rubella Laboratory Network MeV

Testing of retained concentrates from wastewater samples

A total of 2149 wastewater concentrates had been stored after processing of grab samples collected across nine provinces between 16 February 2021 (week 7) and 08 March 2024 (week 10). Limpopo, Mpumalanga, North West and the Northern Cape provinces accounted for only 58 samples (2.6%) as sampling from these sites commenced late or ceased early (see Table 3). Retained concentrates underwent extraction and duplex dPCR in batches between November 2023 and March 2024 (RuV results not presented here). Of the total, 43 samples (2%) tested positive for MeV (Table 3). The majority of wastewater samples were collected in Gauteng province (n=1492), which also had the highest percentage of samples positive for MeV (31, 2.1%, Table 3). No MeV was detected in wastewater from the provinces with the lowest numbers of tested samples (Table 3). Over the three-year period, the majority of positive samples were identified in 2024 (Figure 4, Figure S1). In total, 103 wastewater samples were collected during the vaccination campaign, of which 4 (3%) tested positive for MeV. The median MeV concentration amongst positive samples was 2.12 (2.04-2.25) gc/mL. Pepper mild mottle virus was detected in all wastewater samples at a median concentration of 441 (276-1528) gc/mL. The median ratio of MeV:PMMoV was 441×10^{-3} (range 276×10^{-3} -1528×10^{-3}).

Table 3. Wastewater samples tested for measles virus by digital PCR April 2021 – March 2024 by province and by district of Gauteng Province. The median concentration (and inter-quartile range) of measles virus (MeV) is reported in genome copies/uL from all positive samples. Quantitative results for pepper mild mottle virus (PMMoV) are reported similarly though all samples tested positive for PMMoV.

Province	District	Time period		Samples tested (N)	MeV detected (n, %)	MeV concentration in gc/mL (median, IQR)	PMMoV concentration in gc/mL (median, IQR)	Ratio MeV: PMMoV $\times10^3$ (median, IQR)
		Start	**End**					
Eastern Cape	**Buffalo City and Nelson Mandela Metro**	April 2021	March 2024	187	3 (1.6)	2.12 (2.05-6.4)	404 (346-504)	7.37 (5.33-16.9)
Free State	**Mangaung**	August 2021	March 2024	183	3 (1.6)	2.17 (2.07-4.12)	310 (155-548)	11.17 (6.96-15.37)
Gauteng	**City of Tshwane**	April 2021	March 2024	637	13 (2)	2.12 (2.08-6.11)	1017 (338-2871)	3.27 (1.11-8.04)
Gauteng	**City of Ekurhuleni**	February 2021	March 2024	547	13 (2.4)	2.11 (2.04-2.19)	442 (316-1421)	5.54 (1.43-15.78)

Gauteng	City of Johannesburg	April 2021	March 2024	308	5 (1.6)	2.14 (2.11-2.16)	177 (123-199)	11.29 (10.96-17.9)
KwaZulu-Natal	eThekwini	August 2021	March 2024	149	5 (3.4)	2.04 (2.04-4.17)	1079 (387-2343)	4.08 (0.87-5.27)
North West	Bojanala	November 2023	March 2024	22	0	-	1231 (653-1914)	-
Northern Cape	Namakwa	August 2021	May 2022	14	0	-	927 (505 - 105)	-
Western Cape	City of Cape Town	August 2021	March 2024	72	1 (1.4)	2.1	1934	1.1
Mpumalanga	Ehlanzeni	February 2024	March 2024	10	0	-	616 (217- 821)	-
Limpopo	Mopani	February 2024	March 2024	12	0	-	370 (201 - 740)	-
South Africa		February 2021	March 2024	2149	43 (2)	2.12 (2.04-2.25)	441 (276-1528)	5.27 (1.7-15.72)

344   MeV=measles virus, PMMoV-pepper mild mottle virus, IQR=inter-quartile range

Figure 4: Epidemiological curve showing the number of laboratory- confirmed measles cases (measles IgM positive) submitted to the National Institute for Communicable Diseases as part of fever-rash surveillance (green bars) and the number of wastewater samples in which measles virus was detected by digital PCR (blue bars) by epidemiological week (from 2021 week 7 to 2024 week 10) from A) South Africa, and B) Gauteng Province.

Comparison of clinical surveillance and wastewater measles testing

We identified 481 epidemiological week-districts where both wastewater samples and clinical diagnostic tests were submitted for surveillance. Amongst week-districts, some districts had multiple wastewater samples (median=2, range 1-19 samples) for a given week from a number of sampling locations (n=1-7), while 357 week-district pairs had more than one positive clinical case per week, ranging from 1-104 cases, with a median of 3 cases per week.

Amongst all week-district pairs, measles was identified by both wastewater and clinical surveillance in 2.9% (14) pairs and by neither wastewater nor clinical surveillance in 343 (71%) of pairs (Table 4). Discordance was observed in the remaining 124 (25.8%) of week-district pairs of which the larger proportion (23.1%) were those with negative wastewater samples in districts where clinical cases were detected. When the time frame for a concordant positive test was broadened to include the presence of clinical cases up to a week before or after a positive wastewater sample, the number of positive concordant pairs increased to 17 (3.5%), whilst the number of time-district pairs where wastewater detected evidence of measles and clinical surveillance failed to detect a case, decreased to 10 (2.1%, Table 4). No dose-relationship was discernable between the concentration of MeV detected in wastewater and the number of laboratory-confirmed cases in the same district and epidemiological week (Figure S2). Amongst discordant week-district pairs where MeV was detected in wastewater

375 (Table 5), no clinical testing was conducted in nine districts during that week, whilst 1-15 laboratory-

376 confirmed cases of measles were identified in eight of 14 neighbouring districts.

377 **Table 4. A comparison of wastewater and clinical testing results in the same district and**
378 **epidemiological week for surveillance conducted between epidemiological week 7, 2021 to**
379 **epidemiological Week 10, 2024.**

Part A: same epidemiological week		Wastewater Results		
		Positive	Negative	Total
Clinical Results (IgM)	Positive (IgM)	14 (2.9%)	111 (23.1%)	125
	Negative (IgM)	13 (2.7%)	343 (71.3%)	356
	Total	27	454	481
Part B: same epidemiological week + clinical results one week before and one after		Wastewater Results		
		Positive	Negative	Total
Clinical Results (IgM)	Positive (IgM)	17 (3.5%)	190 (39.5%)	207
	Negative (IgM)	10 (2.1%)	264 (54.9%)	274
	Total	27	454	481

381 **Table 5. Fever-rash surveillance results for epidemiological weeks and districts where**
382 **wastewater samples tested positive for measles RNA during epidemiological week 7, 2021 to**
383 **epidemiological Week 10, 2024. Epidemiological weeks are designated with the year followed by**
384 **the week number.**

Epidemiological week	District	District under observation		Clinical cases in neighbouring districts		
		Wastewater (positive/total)	Clinical (IgM +/total)	Cases in that week	Cases the week before	Cases the week after
2021-W45	Ekurhuleni	1/2	.	0	0	0
2021-W45	Tshwane	1/2	.	0	0	0
2022-W04	Buffalo city	1/2	.	0	0	0
2022-W04	Ekurhuleni	1/2	0/2	2	0	2
2022-W05	Ethekwini	1/2	.	0	0	0
2022-W07	Buffalo city	1/2	.	0	0	0
2022-W18	Tshwane	1/2	0/2	1	0	1
2022-W42	Ekurhuleni	1/2	.	5	4	5
2023-W12	Ethekwini	1/1	0/6	0	1	1
2023-W12	Mangaung	1/2	0/2	4	1	1
2023-W15	Ekurhuleni	1/1	0/1	15	15	7
2023-W20	Johannesburg	1/6	.	9	12	12
2023-W25	Ethekwini	1/1	.	0	0	0
2023-W33	Ekurhuleni	1/5	0/1	7	4	9
2023-W37	Buffalo city	1/4	.	0	0	0
2023-W37	Ekurhuleni	1/10	0/1	2	9	12

4. Discussion

We successfully developed and validated a duplex dPCR for the detection of measles virus in
wastewater. On application to retained wastewater concentrates sampled from national and sentinel
site surveillance during an ongoing measles outbreak in South Africa, the assay detected MeV RNA at
copy numbers ranging from 1.97 – 165.8 gc/mL in 43 (2%) of wastewater samples. Despite likely
RNA decay on account of sample storage, in an analysis based on district-time pairs, we observed
positive MeV wastewater detections in health districts where no clinical cases were detected. This
observation, together with recent global results of MeV WES testing during outbreaks illustrate that
wastewater surveillance should be explored using real-time sampling and strengthened laboratory test
methods for MeV, to explore how data emerging from MeV WES may complement clinical fever-
rash surveillance for measles cases, and if MeV WES may have value as a programmatic surveillance
tool.

We believe these detections of MeV in wastewater are representative of measles infections in the
catchment area and health district, and that this has public health significance, despite the low
concentrations of MeV in our samples. Firstly, it is to be expected that MeV will be present in
wastewater as the virus is excreted in urine by infected persons [25,26]. Further, grab sampling,
despite being an instantaneous sample, may provide useful results even if few clinical cases are
present in a sewershed because dispersal of virus occurs the sewerage network due to differing
gradients, varying flow rates and entrapment in sediment[27]. Our findings are not unique – even
though we found MeV in low copy numbers, we know this is likely because of the well-established
loss of RNA following freeze-thaw cycles [14,28], and even with real time sampling, other authors
have also detected MeV in wastewater in an outbreak context in low copy numbers ranging from 2-
22gc/mL[9,13,15,16]. Our analytic approach further demonstrates the public health significance of
our findings, in that by comparing wastewater and clinical surveillance data at a district level, and by
epidemiological week, we provide results to support the WHO definition of a measles outbreak (a
threshold of 2-5 cases *per district* in one month is required before initiating appropriate public health
interventions[24,29]), and identify instances where measles transmission is evident despite the
absence of clinical cases. Programmatic fever-rash and laboratory-based surveillance for measles has
never had a way to demonstrate surveillance sensitivity, because there was no way of demonstrating
MeV transmission where case detection is limited by patient health seeking behaviour, health system
issues and clinician failure to submit laboratory tests for measles. Detractors may argue that
wastewater surveillance also lacks sensitivity, as in our study, wastewater surveillance was not always
positive in districts where laboratory-confirmed measles cases were detected. This is likely due to the
intrinsic limitations of wastewater detection for viral RNA targets, such as viral decay in wastewater
matrix, and/or excessive dilution, or timing of sampling, but also geographical mismatch between
case location and wastewater catchment area, and RNA decay during storage and freeze-thaw cycles.
However, these limitations do not detract from the value of positive wastewater detections that

highlight deficiencies in clinical surveillance programmes. Put together, the public health value of
measles wastewater surveillance lies in its ability to detect active measles transmission where clinical
surveillance fails to detect cases.

In the light of the public health significance of measles WES, consideration may be given to potential
roles of WES in measles control and elimination. In areas where fever-rash surveillance is weak or
absent, as may be the case in resource poor settings, wastewater surveillance may indicate the
presence and extent of community transmission of MeV. Where measles is not endemic, or measles
outbreaks are not ongoing and especially where vaccination coverage is less than 95%, wastewater
detections of MeV may provide early detection signals that herald the onset of outbreaks. The
potential for sequencing of MeV from wastewater has been demonstrated [30], and the genomic
analyses that are conducted may be useful to complement data obtained from sequencing clinical
strains, or to provide genomic data in resource-poor contexts where samples appropriate for molecular
detection and sequencing (throat swab or urine) are not submitted for testing. The additional genomics
data and phylogenetic analysis obtained from wastewater-derived sequences will strengthen measles
control in the same way that environmental surveillance has strengthened polio control, particularly if
whole genome MeV sequencing replaces the n450 genotyping methods currently in use[31].

Lastly, if WES for measles is to be included in programmatic control, public health interventions that
should follow detection of MeV in wastewater need to be established. Following detection of certain
polio strains in wastewater, the WHO guidelines require district-wide SIAs. Following detection of
laboratory-confirmed clinical measles cases, WHO presently recommends case investigation and
diagnostic testing, contact tracing with ring vaccination, case finding, and district wide supplementary
immunisation activities (SIA) if a threshold of cases (two to five cases per health district per month)
are identified[24]. WES measles detection will not facilitate case identification but may identify
vulnerable communities where clinical surveillance should be strengthened. As the sensitivity of
WES MeV surveillance becomes clearer, it may become evident if WES MeV detection should
trigger a supplementary immunization activity.

Lastly, our findings were limited by likely RNA decay discussed above, and by our inability to design
primers and probes with sufficient sensitivity and specificity to differentiate MeV-WT from vaccine
strain (MeV genotype A). This meant that we were unable to rule out the presence of genotype A, and
to rule out the presence MeV-WT if genotype A was detected. This is not surprising given the
marked similarity between genotypes A, B3, D8 and H1 in the N gene region selected for primer
design. Even when applied to clinical samples, differentiating WT from vaccine without sequencing is
challenging, often relying on probes that differ by a single nucleotide[32,33]. Under these
circumstances, differences in Ct thresholds between MeV-WT and vaccine-specific probes rather than
presence/absence signals are helpful to distinguish the two[34]. In a similar way, Wu et al[14]

successfully achieved WT vs vaccine differentiation in wastewater samples using primer-probe
combinations targeting the M gene. Their format relies on differences in dPCR amplitudes (indicative
of degree of fluorescence) emanating from positive partitions to differentiate WT from vaccine,
relying on the principle that mismatched probes release less fluorescent dye following incomplete
breakdown by the exonuclease function of Taq polymerase. Our laboratory is presently testing the Wu
method in parallel with routine testing of wastewater for MeV.

However, vaccinated, non-immune persons secrete lower levels of vaccine virus and for a shorter
duration, leading to lower inoculum sizes in wastewater. Therefore, it is much more likely that MeV
detected in wastewater is wild type strain, so even without the ability to differentiate WT-MeV from
vaccine strain, wastewater detection remains useful. The evidence base for this hypothesis is as
follows: Firstly, no onward transmission of vaccine strain has ever been documented suggesting that
vaccine excretion rates are low[35]. Shedding duration in WT measles cases may be as long as 26-61
days post infection[26], whilst Walsham et al reported median PCR detection of measles vaccine in
urine post MMR vaccination of 11 days, (IQR 9,2 days)[36]. Lastly, routine EPI measles vaccination
is administered to infants who are in diapers and may not contribute to wastewater, and even during a
measles SIA, most vaccine recipients have seroprotective antibodies that prevent viraemia.

A further laboratory consideration and potential limitation of our work is the lack of clarity regarding
the need for a normalization step to MeV detection results. Normalisation may remove apparent
fluctuations in pathogen concentration when changes in wastewater volume (e.g. through rain) occur
and may allow for elimination of 'noise' or false signals. However, in an elimination context, as with
polio, pathogen concentrations are of less significance compared to detection results. Nonetheless, we
elected to use PMMoV concentrations in wastewater, a reliable marker of fecal load. The ratios of
MeV:PMMoV were largely constant across sewersheds, differing only by 1 log, and did not reflect
the large increase in measles cases during the 2022-23 outbreak, likely because RNA decay in our
retained concentrates may have hidden this signal.

Finally, our analysis strategy and positive findings, even though only a small percentage of
wastewater samples tested positive, together suggest that real-time WES for measles holds promise to
support the global measles and rubella elimination agendas. Evaluation of more efficient wastewater
concentration, extraction and detection methods for MeV to improve sensitivity and provide sufficient
material for genotyping are desirable. Measles WES with real-time wastewater sample processing
should be integrated into clinical measles surveillance programmes in routine contexts to accumulate
experience and data to allow for evaluation of the relative contribution of this novel surveillance
modality to measles control and elimination.

Acknowledgements

We would like to acknowledge the contribution of the NICD Centre for Vaccines and Immunology for use of the polio environmental laboratory, and measles surveillance data (also approved by Wits HREC). We thank the municipal workers, and NICD drivers who collected and transported certain wastewater samples. We thank our sample collectors Lebohang Rabotapi, Lethabo Monametsi, and laboratory technicians Thabo Mangena, Mantshali Motloung for collecting and initial processing of the samples, and our administrator Namhla Madikane for her helpful support and willingness to go to the field when necessary. Thank you to Dr Colleen Bamford for attention to detail and finalizing the manuscript.

Supplementary material

References

1. WHO. Measles and Rubella Strategic Framework: 2020-2030. Geneva: WHO; 2020. Available: https://www.who.int/publications/i/item/measles-and-rubella-strategic-framework-2021-2030

2. Minta AA, Ferrari M, Antoni S, Portnoy A, Sbarra A, Lambert B, et al. Progress Toward Measles Elimination - Worldwide, 2000-2022. MMWR Morb Mortal Wkly Rep. 2023;72: 1262–1268. doi:10.15585/mmwr.mm7246a3

3. Ntshoe GM, McAnerney JM, Archer BN, Smit SB, Harris BN, Tempia S, et al. Measles outbreak in South Africa: epidemiology of laboratory-confirmed measles cases and assessment of intervention, 2009-2011. PloS One. 2013;8: e55682. doi:10.1371/journal.pone.0055682

4. WHO. Surveillance Standards for Vaccine-Preventable Diseases, Second Edition. WHO; 2018. Available: https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/surveillance/surveillance-for-vpds/vpd-surveillance-standards

5. Patel MK, Gibson R, Cohen A, Dumolard L, Gacic-Dobo M. Global landscape of measles and rubella surveillance. Vaccine. 2018;36: 7385–7392. doi:10.1016/j.vaccine.2018.10.007

6. Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic Plan 2012-2020 midterm review. Vaccine. 2018;36 Suppl 1: A1–A34. doi:10.1016/j.vaccine.2017.09.026

7. Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet Lond Engl. 2022;399: 678–690. doi:10.1016/S0140-6736(21)02004-3

8. Kilaru P, Hill D, Anderson K, Collins MB, Green H, Kmush BL, et al. Wastewater Surveillance for Infectious Disease: A Systematic Review. Am J Epidemiol. 2023;192: 305–322. doi:10.1093/aje/kwac175

9. Benschop KSM, van der Avoort HG, Jusic E, Vennema H, van Binnendijk R, Duizer E. Polio and Measles Down the Drain: Environmental Enterovirus Surveillance in the Netherlands, 2005 to 2015. Appl Environ Microbiol. 2017;83: e00558-17. doi:10.1128/AEM.00558-17

10. Hayes EK, Gouthro MT, LeBlanc JJ, Gagnon GA. Simultaneous detection of SARS-CoV-2, influenza A, respiratory syncytial virus, and measles in wastewater by multiplex RT-qPCR. Sci Total Environ. 2023;889: 164261. doi:10.1016/j.scitotenv.2023.164261

11.   Roman V, Jourdain F, Pele E, Brottet E, Guinard A, Mouly D, et al. Tracking wild-type measles virus
in wastewater using multiplex RT-dPCR, A novel tool for measles surveillance. Water Res. 2025;287: 124379.
doi:10.1016/j.watres.2025.124379

12.   Tomalty E, Mercier É, Pisharody L, Nguyen T, Tian X, Kabir MP, et al. Detection of Measles Virus
Genotype A in a Non-Endemic Wastewater Setting: Insights from Measles Wastewater and Environmental
Monitoring in Canada's Capital Region. Environ Sci Technol Lett. 2025;12: 124–129.
doi:10.1021/acs.estlett.4c00945

13.   Rector A, Bloemen M, Hoorelbeke B, Ranst MV, Wollants E. Detection of measles virus genotype D8
in wastewater of Brussels capital region, Belgium, March 2024. medRxiv; 2024. p. 2024.04.08.24305478.
doi:10.1101/2024.04.08.24305478

14.   Wu J, Wang MX, Kalvapalle P, Nute M, Treangen TJ, Ensor K, et al. Multiplexed detection,
partitioning, and persistence of wild type and vaccine strains of measles, mumps, and rubella viruses in
wastewater. medRxiv; 2024. p. 2024.05.23.24307763. doi:10.1101/2024.05.23.24307763

15.   Gan C, Pitton M, de Korne-Elenbaas J, Cobuccio L, Cassini A, Ort C, et al. Retrospective Wastewater
Tracking of Measles Outbreak in Western Switzerland in Winter 2024. Environ Sci Technol Lett. 2025;12: 689–
694. doi:10.1021/acs.estlett.5c00244

16.   Langan LM, Bain FL, Snow CC, Oldfather J, Sagvold O, Kaneshiro K, et al. Spatially Informed
Wastewater Differentiation among Locations during an Ongoing Measles Outbreak in Texas, USA. ACS
Environ Au. 2025;5: 543–549. doi:10.1021/acsenvironau.5c00122

17.   McCarthy K, Maposa S, Mabasa V, Singh N, Gwala S, Sankar C, et al. Wastewater surveillance for
infectious agents of measles, rubella, hepatitis, influenza, mpox, and tuberculosis in South Africa, 2024. Public
Health Bull South Afr. 2025;3: 127–150.

18.   Yoshioka N, Hagiya H, Deguchi M, Hamaguchi S, Kagita M, Tomono K. Simultaneous and rapid
detection method for measles and rubella using single-tube multiplex real-time quantitative RT-PCR. J Infect
Chemother Off J Jpn Soc Chemother. 2019;25: 829–831. doi:10.1016/j.jiac.2019.05.005

19.   Cantillon D, Roberts AP. Development and evaluation of TaqMan-based, one-step, real-time RT-PCR
assays for pepper mild mottle virus detection for near source tracking and wastewater-based epidemiology
validation. PloS One. 2022;17: e0278784. doi:10.1371/journal.pone.0278784

20.   Chen M-H, Abernathy E, Icenogle JP, Perelygina LM. Improved diagnostic and multiplex RT-qPCR
for detecting rubella viral RNA. J Virol Methods. 2022;306: 114555. doi:10.1016/j.jviromet.2022.114555

21.   World Health Organization. Manual for the laboratory-based surveillance of measles, rubella, and
congenital rubella syndrome. Geneva, Switzerland; 2018. Available: https://www.who.int/immunization/
monitoring_surveillance/burden/laboratory/manual/en/

22.   Hummel KB, Lowe L, Bellini WJ, Rota PA. Development of quantitative gene-specific real-time RT-
PCR assays for the detection of measles virus in clinical specimens. J Virol Methods. 2006;132: 166–173.
doi:10.1016/j.jviromet.2005.10.006

23.   Yousif M, Hong H, Malfeld S, Smit S, Makhathini L, Motsamai T, et al. Measles incidence in South
Africa: a six-year review, 2015-2020. BMC Public Health. 2022;22: 1647. doi:10.1186/s12889-022-14069-w

24.   WHO. Measles outbreak guide. Geneva, Switzerland: WHO; 2022. Available:
https://www.who.int/publications/i/item/9789240052079

25.   Forthal DN, Aarnaes S, Blanding J, de la Maza L, Tilles JG. Degree and Length of Viremia in Adults
with Measles. J Infect Dis. 1992;166: 421–424. doi:10.1093/infdis/166.2.421

26.   Permar SR, Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, et al. Prolonged measles virus shedding
in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain
reaction. J Infect Dis. 2001;183: 532–538. doi:10.1086/318533

27.   Hovi T, Stenvik M, Partanen H, Kangas A. Poliovirus surveillance by examining sewage specimens.
Quantitative recovery of virus after introduction into sewerage at remote upstream location. Epidemiol Infect.
2001;127: 101–106. doi:10.1017/s0950268801005787

28.   Rusiñol M, Martínez-Puchol S, Forés E, Itarte M, Girones R, Bofill-Mas S. Concentration methods for
the quantification of coronavirus and other potentially pandemic enveloped virus from wastewater. Curr Opin
Environ Sci Health. 2020;17: 21–28. doi:10.1016/j.coesh.2020.08.002

29.   WHO. WHO African Regional measles and rubella surveillance guidelines. WHO AFRO; 2015.
Available: https://www.afro.who.int/publications/who-african-regional-measles-and-rubella-surveillance-
guidelines-0

30.   Javornik Cregeen S, Tisza MJ, Hanson B, Cook M, Surathu A, Schneider R, et al. Sequencing-Based
Detection of Measles in Wastewater: Texas, January 2025. Am J Public Health. 2025;115: 1115–1119.
doi:10.2105/AJPH.2025.308146

31.   Bankamp B, Kim G, Hart D, Beck A, Ben Mamou M, Penedos A, et al. Global Update on Measles
Molecular Epidemiology. Vaccines. 2024;12: 810. doi:10.3390/vaccines12070810

32.   Tran T, Kostecki R, Catton M, Druce J. Utility of a Stressed Single Nucleotide Polymorphism (SNP)
Real-Time PCR Assay for Rapid Identification of Measles Vaccine Strains in Patient Samples. J Clin Microbiol.
2018;56: e00360-18. doi:10.1128/JCM.00360-18

33.   Roy F, Mendoza L, Hiebert J, McNall RJ, Bankamp B, Connolly S, et al. Rapid Identification of
Measles Virus Vaccine Genotype by Real-Time PCR. J Clin Microbiol. 2017;55: 735–743.
doi:10.1128/JCM.01879-16

34.   Stanoeva KR, Kohl RHG, Bodewes R. Co-detection of the measles vaccine and wild-type virus by
real-time PCR: public health laboratory protocol. Access Microbiol. 2021;3: 000283.
doi:10.1099/acmi.0.000283

35.   Greenwood KP, Hafiz R, Ware RS, Lambert SB. A systematic review of human-to-human transmission
of measles vaccine virus. Vaccine. 2016;34: 2531–2536. doi:10.1016/j.vaccine.2016.03.092

36.   Washam MC, Leber AL, Oyeniran SJ, Everhart K, Wang H. Shedding of measles vaccine RNA in
children after receiving measles, mumps and rubella vaccination. J Clin Virol Off Publ Pan Am Soc Clin Virol.
2024;173: 105696. doi:10.1016/j.jcv.2024.105696

603